Pharmacogenomics Pioneer HairDX Names David Teckman President and CEO
HairDX, LLC (www.hairdx.com), an FDA registered pharmacogenomics research and development company today named David R. Teckman as its new President and CEO. HairDX specializes in testing and genetic analysis of skin disorders and hair biology.
Teckman is a seasoned executive with over 30-years experience in many facets of healthcare. He was recently President and CEO of Sutura, Inc (SUTU) a medical device manufacturer in Orange Country, California where he led a successful turnaround effort.
He went to Sutura after serving as Director of Whitebox Advisors, a $4 billion hedge fund headquartered in Minneapolis, MN. He is currently Chairman of the Board of InstyMeds, a Minneapolis based provider of automated prescription dispensing solutions for acute care settings.
Previously, Teckman was President and CEO of Vivius, a provider of personalized health insurance solutions, President of Disc Systems, a physician practice management software company, Senior Vice President, of PCS Health Systems, a pharmacy benefit management company, Executive Director of Equior Health Plans and National Sales manager of Infomed Corporation.
Teckman is a graduate of Miami University (Oxford, OH) with a Bachelors Degree in Business Administration.
Andy Goren, HairDX former CEO is moving to the role of Chairman & Co-Founder. “By bringing in an industry veteran like David Teckman, HairDX is poised to move forward as an innovator and leader in pharmacogenomics and healthcare research and development,” said Goren.
“The marriage of genetic testing and pharmacological solutions is one of the next new and interesting opportunities in healthcare,” said Teckman. “Like many conditions, hair loss can be determined through early screening and in conjunction with a physician preventative actions can be taken. I am pleased to have the opportunity to join the HairDX team.”
Earlier this year, HairDX became the first company to market genetic tests that predict an individual’s risk for the male or female versions of Androgenetic Alopecia (Hair Loss). The test is available in the US through qualified physicians.
HairDX uses a CLIA certified laboratory (Clinical Laboratory Improvement Amendments) to perform the genetic analysis, offering physicians a powerful screening test for Androgenetic Alopecia before any visible signs of hair loss. The HairDX test results can assist a physician in choosing a course of action as to maintain a patient’s hair.
About HairDX, LLC
HairDX, LLC is a subsidiary of PharmaGenoma, Inc. Based in Irvine, CA, HairDX (www.hairdx.com) HairDX is an FDA registered pharmacogenomics research and development company. HairDX markets the first genetic test for male and female hair loss. The company is dedicated to the research and development of new prescription based therapies tailored to an individual’s genetic make up.
Among HairDX leaders is William V. Murray former Division President of the Molecular Biology Division of Applied BioSystems, Inc., who formerly served in various executive leadership positions within Medtronic, Inc., Andy Goren former CEO of MobileWise, Inc. and GeePS, Inc., David Teckman, former CEO of Sutura, Inc, a medical device company, Professor Doron Lancet, PhD, Head of the Crown Human Genome Center at the Department of Molecular Genetics, Weizmann Institute of Science, Dr Elon Pras, Director of the Institute of Human Genetics, Sheba Medical Center in Tel-Hashomer, Israel, Sharon Keene, MD and President and Medical Director of Physician’s Hair Institute, in Tucson, Arizona and nationally recognized for her pioneering work in the hair transplant field, and Elliott J. Stein, an intellectual property attorney and co-founder of GeePS, Inc.